BioCentury
ARTICLE | Company News

Actelion infectious, inflammation, cardiovascular news

July 23, 2012 7:00 AM UTC

At June 30, the company had CHF1.4 billion ($1.5 billion) in cash including CHF378.9 ($396.4 million) in restricted cash and a six-month operating gain of CHF229.2 million ($239.8 million). The company spent CHF232.1 million ($242.8 million) on R&D in the first half of 2012. ...